EarningsQ2 2026 Earnings Report
MX:RPRXN Q2 2026 EPS Results
Actual EPS$24.33
Consensus EPS$23.44
Beat/MissBeat by +$0.88
One Year Ago EPS$21.01
MX:RPRXN Q2 2026 Revenue Results
Actual Revenue$12.41B
Expected Revenue$13.98B
Beat/MissMissed by -$1.56B
YoY Revenue Growth+16.50%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
MX:RPRXN Upcoming Earnings
Royalty Pharma's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:RPRXN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.Company Guidance
Double‑digit recurring cash flow growth
Royalty receipts (recurring cash flows) grew 14% year‑over‑year in Q2 2026; portfolio receipts (top line) grew 6% to $773 million, slightly ahead of expectations.
Raised full‑year 2026 guidance
Management increased 2026 portfolio receipts guidance to $3.4B–$3.5B (up from $3.325B–$3.45B), with expected royalty receipt growth of ~7%–10% (prior 4%–8%).
Strong returns on capital and equity
Return on invested capital for the last 12 months was 14.2% and return on invested equity was 20.1%, underlining attractive investment returns.
Material capital deployment and attractive deal flow
Deployed $1.1 billion of capital on royalty acquisitions year‑to‑date (announced value $1.7B); $877 million deployed in H1 2026 overall, demonstrating active deal execution.
Strategic cliramitug acquisition with blockbuster potential
Acquired a portion of Neurimmune's royalty on AstraZeneca's cliramitug for up to $425M (3.75% royalty). AstraZeneca projects peak sales of $3B–$5B; Royalty Pharma expects peak royalties ~$110M–$190M and an internal rate of return in the teens (development‑stage target range).
Expanded and de‑risked development‑stage pipeline
Development‑stage pipeline increased from 3 at IPO to 19 today (6x); peak potential royalties from late‑stage pipeline ~ $2B and company cites ~90% historical success rate for development‑stage investments progressing to approval.
Strong cash generation, balance sheet and credit upgrade
Portfolio cash flow (adjusted EBITDA less net interest) was $736M in the quarter with ~95% cash conversion. Cash & equivalents $812M; investment grade debt $9.2B; leverage ~2.8x total debt/adjusted EBITDA (2.6x net). S&P upgraded rating in June to BBB across agencies.
Meaningful shareholder returns
Returned ~ $370M to shareholders in H1 (dividends and buybacks), repurchased ~5 million shares in the quarter (~1% reduction in weighted average share count). Returned ~25% of portfolio cash flow to shareholders YTD.
MX:RPRXN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed